Neurocrine Biosciences | NBIX - Gross Profit On Sales



Neurocrine Biosciences reported $676.2M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
ALKERMES USD 257.77M 462K Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Amgen USD 6.17B 624M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Cytokinetics 66.77M 165.03M Jun/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Exelixis USD 548.79M 12.52M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Halozyme Therapeutics USD 279.36M 62.9M Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Prothena -36100000 22.9M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Repligen USD 91.14M 385K Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
Teva Pharmaceutical Industries USD 2.1B 188M Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025